Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease.
A prominent feature of sickle cell disease is the presence of cells with markedly increased sickle cell hemoglobin concentration, as a consequence of the loss of potassium, chloride, and water from the erythrocyte. Because of the extreme dependency of the kinetic of polymerization on sickle cell hemoglobin concentration, these dehydrated erythrocytes have an increased tendency to polymerize and sickle. Thus blockade of the loss of potassium from the erythrocyte should prevent the increase in sickle cell hemoglobin concentration and reduce sickling. The availability of this potential therapeutic option is based on a detailed knowledge of the mechanisms leading to cell dehydration. Two ion transport pathways, the K-Cl cotransport and the Ca(2+)-activated K+ channel, play a prominent role in the dehydration of sickle erythrocytes. Possible therapeutic strategies include inhibition of K-Cl cotransport by increasing erythrocyte Mg2+ content and inhibition of the Ca(2+)-activated K channel by oral administration of clotrimazole.
Brugnara
C
C
Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
D000755:Anemia, Sickle Cell / Q000188:drug therapy* / Q000503:physiopathology; D000935:Antifungal Agents / Q000627:therapeutic use; D003022:Clotrimazole / Q000627:therapeutic use; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D008274:Magnesium / Q000097:blood; D015221:Potassium Channels / Q000187:drug effects; D000254:Sodium-Potassium-Exchanging ATPase
D000935:Antifungal Agents; D015221:Potassium Channels; D000254:Sodium-Potassium-Exchanging ATPase; D003022:Clotrimazole; D008274:Magnesium